Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPI0AX)

• Drug Name: (S)-BULBOCAPNINE Drug Info
• Synonyms: Bulbocapnine; 298-45-3; UNII-O0TGI865QO; Bulbokaprin; O0TGI865QO; CHEMBL157912; CHEBI:3211; (S)-BULBOCAPNINE; EINECS 206-061-1; Bulbocapnin; Buibocapnine hydrochloride; AC1L1ZLR; 632-47-3; ZINC103; SCHEMBL678694; 6a-alpha-APORPHIN-11-OL, 10-METHOXY-1,2-(METHYLENEDIOXY)-; AC1Q703Q; DTXSID20183940; BDBM50016018; 9126AF; PDSP2_000621; ACM298453; AKOS000276822; C09367; 11-Methoxy-7-methyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4'',5'':4,5]benzo[1,2,3-de]quinolin-12-ol (Bulbocapnine)

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 12441
  ChEBI ID: CHEBI:3211
  CAS Number: CAS 298-45-3
  TTD Drug ID: DMPI0AX

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D1 receptor (D1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[2]
Pergolide	DM14MAE	Parkinson disease	8A00.0	Approved	[3]
Methylergonovine	DMBEX4O	Spontaneous abortion	JA00.0	Approved	[4]
Fenoldopam	DMFAOKP	Hypertension	BA00-BA04	Approved	[5]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[6]
Ecopipam	DMS9R43	Cocaine addiction	6C45.2	Phase 3	[7]
DAS-431	DMM3BPL	Dementia	6D80-6D86	Phase 2	[8]
Dihydrexidine	DMACPQO	Psychotic disorder	6A20-6A25	Phase 1/2	[9]
BAM-1110	DMPMKUF	Parkinson disease	8A00.0	Discontinued in Phase 2	[10]
CY-208243	DMP8TKA	Pain	MG30-MG3Z	Discontinued in Phase 2	[11]

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Parkinson disease	8A00.0	Approved	[12]
Haloperidol	DM96SE0	Schizophrenia	6A20	Approved	[13]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[14]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[15]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[16]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[17]
Quetiapine	DM1N62C	Schizophrenia	6A20	Approved	[18]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[19]
Chlorpromazine	DMBGZI3	Schizophrenia	6A20	Approved	[20]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D1 receptor (D1R)	TTZFYLI	DRD1_HUMAN	Inhibitor	[1]
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Inhibitor	[1]

References

• [1] Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.
• [2] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
• [5] Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
• [6] Clinical pipeline report, company report or official report of Lundbeck.
• [7] A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
• [8] Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
• [9] trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
• [10] Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
• [11] The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol. 1988 Nov 1;156(2):197-206.
• [12] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [13] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [14] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [15] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [16] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [18] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [19] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [20] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [21] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.